Fatima Bint Mubarak Center Leads First Clinical Treatment Experience
The Efforts to Combat Breast Cancer
The efforts of the competent companies and experts concerned with cancerous breast tumors continue, in order to achieve serious results about some treatments that can improve the lives of cancer patients in general, and breast cancer patients in particular.
A Promising Clinical Experiment for Breast Tumors and Preventing Cancer from Returning with Emirati Participation
Within the efforts of the UAE to combat this disease and improve the quality of the lives of citizens and its residents, the Fatima Bint Mubarak Center of Cleveland Clinic Abu Dhabi seeks part of a group to participate in research and clinical experiences currently on the aim of reaching revolutionary treatments for breast cancer.
What Do We Know About This Experience? Here are More Details in the Following Lines.
The experiment focuses on a specific drug from the family of selective reduction of estrogen receptors (Serd) The designer for blocking futures more efficiently compared to the drugs currently available. This study aims to compare the new drug with current hormonal treatments to monitor its efficiency in reducing the chances of repeating cancer.
Fatima Bint Mubarak Center is the First to Participate in a Clinical Treatment Experience
The study aims to assess a new drug that reduces the risk of breast cancer. So, the Fatima Bint Mubarak Center has become the first participant in this revolutionary experience that Astrazinica is funded at the level of the Arab Gulf states.
Therapeutic Clinical Experiments Bear a Lot of Hope for Those Recovering from Breast Cancer
Dr. Stephen Groubmaire, head of the Institute of Oncology at the Cleveland Clinic Abu Dhabi Hospital, stressed the importance of such clinical experiences, adding: "Clinical experiences are very uncommon in the Gulf Cooperation Council countries, which causes widespread concern about equality matters in the health sector. Therefore, our participation in this clinical experience involved in breast cancer comes to reflect our commitment to placing the best therapeutic options within the reach of patients, coinciding with the enrichment of global knowledge on how such treatments affect different population slices.
Conclusion
The clinical study, which reached its third stage, includes about 5,500 thousand participants around the world. The participation of the Fatima Bint Mubarak Center is established in it its pioneering position in tumor care and support for global research. By facilitating the ways to reach advanced clinical trials, the center is committed to the current gap bridge in the field of care and providing patients in the region with the most developed therapeutic options.
Frequently Asked Questions
- What is the purpose of the CAMBRIA-2 study?
The purpose of CAMBRIA-2 is to know if the new drug (Serd) is better to reduce the opportunity to return cancer compared to the usual hormonal treatments such as litroosol, inastrozol, eczemstan or tamoxifin. - What is the goal of the study?
The goal of the study is to compare the new drug (Serd) with current hormonal treatments to monitor its efficiency in reducing the chances of repeating cancer. - Why is the Fatima Bint Mubarak Center participating in this study?
The center is participating in this study to reflect its commitment to placing the best therapeutic options within the reach of patients, coinciding with the enrichment of global knowledge on how such treatments affect different population slices.